本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

CSL LIMITED

234.340
-5.640-2.35%
成交量:122.37萬
成交額:2.90億
市值:1,134.70億
市盈率:27.03
高:240.040
開:238.520
低:234.140
收:239.980
資料載入中...

公司資料

公司名字:
CSL LIMITED
交易所:
ASX
成立時間:
1916
員工人數:
32698
公司地址:
655 Elizabeth Street,Melbourne,Victoria,Australia
郵編:
3000
傳真:
61 3 9389 1434
簡介:
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.